UNSPSC 51286706: Talmetoprim

This classification denotes a topical anti-infective agent with the molecular formula C22H20N4O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X8W4CW0QHK, chemically known as 2-(4-amino-5-((3,4,5-trimethoxyphenyl)methyl)-2-pyrimidinyl)-1h-isoindole-1,3(2h)-dione but more generally known as talmetoprim, which bears US NIH Compound Identifier 163307. European Medicines Agency schedules Talmetoprim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10809MIG.

The term TALMETOPRIM is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 33, No. 10 1979, List 19). TALMETOPRIM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

UNSPSC 51286706 Talmetoprim is a Commodity code covering antimicrobial pharmaceutical products. State and local governments solicit under this code to stock emergency response inventories, public health reserves, and community health initiatives with essential medications. The recent opportunities show purchase of naloxone and drug deactivation systems for public health use, as well as broad pharmaceutical warehouse contracts through cooperative purchasing vehicles such as MMCAP Infuse. Issuing bodies include state health departments and county government health agencies; these jurisdictions typically procure through piggyback contracts on established cooperative purchasing consortiums or through competitive sealed bids for specific product quantities and delivery schedules.

Activity appears concentrated in Florida and Illinois based on recent postings. Seminole County, Florida released an IFB on June 30, 2026 to procure 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with a response deadline of July 26, 2026, requiring quarterly deliveries to the Seminole County Community Health Building in Sanford; the Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical warehouse contract through MMCAP Infuse to Chartwell Rx LLC on August 28, 2026 for Doxycycline Hyclate and Ciprofloxacin Hydrochloride with an initial 12-month term and two renewal options. Cooperative purchasing vehicles dominate the procurement landscape, and vendors entering this market should expect E-Verify compliance, drug-free workplace certifications, and fixed-fee or unit-cost pricing structures with quarterly or annual delivery commitments.